Dolciami, Daniela
Villasclaras-Fernandez, Eloy
Kannas, Christos
Meniconi, Mirco
Al-Lazikani, Bissan
Antolin, Albert A.
Funding for this research was provided by:
Cancer Research UK (C35696/A23187, C35696/A23187, C35696/A23187, C309/A11566)
Wellcome Trust (212969/Z/18/Z, 204735/Z/16/Z)
FP7 People: Marie-Curie Actions (FP7/2007–2013)
Article History
Received: 4 February 2022
Accepted: 4 April 2022
First Online: 28 May 2022
Declarations
:
: DD, EV-F, CK, MM, AAA and BA-L are/were employees of The Institute of Cancer Research (ICR), which has a commercial interest in a range of drug targets. The ICR operates a Rewards to Inventors scheme whereby employees of the ICR may receive financial benefits following the commercial licensing of a project. BA-L is an employee of MD Anderson Cancer Center which also operates a Reward to Inventors Scheme. BA-L declares commercial interest in Exscientia and Astra Zeneca. BA-L is/was a consultant/ scientific advisory board member for GSK, Open Targets, Astex Pharmaceuticals, Astellas Pharma and is an ex-employee of Inpharmatica Ltd. AAA is/was a consultant of Darwin Health. CK is an employee of Astra Zeneca. DD, EV-F, CK, AAA and BA-L have been instrumental in the creation/development of canSAR and/or Probe Miner. BA-L was instrumental in the creation of ChEMBL and is a Director of the non-profit Chemical Probes Portal.